拉米地坦是偏头痛急性治疗的有效药物:一项3期随机研究
本研究为3期随机双盲研究,纳入成人偏头痛患者,按1:1:1随机接受口服拉米地坦200 mg、100 mg或安慰剂治疗下一次偏头痛发作。1856例患者中77.9%至少有一项心血管危险因素。200 mg和100 mg组在给药后2小时无头痛疼痛的比例均高于安慰剂,无最困扰症状的比例也更高,不良事件多为轻中度。
要点
- 拉米地坦200 mg组给药后2小时无头痛疼痛比例为32.2%,高于安慰剂组的15.3%(OR 2.6)。
- 拉米地坦100 mg组给药后2小时无头痛疼痛比例为28.2%,高于安慰剂组(OR 2.2)。
- 拉米地坦200 mg和100 mg组给药后2小时无最困扰症状的比例分别为40.7%和40.9%,均高于安慰剂组的29.5%。
核心结论
- 拉米地坦200 mg和100 mg对心血管危险因素水平较高的成人偏头痛患者的急性治疗有效且耐受性良好。
研究设计与样本
- 3期随机双盲研究,成人偏头痛患者按1:1:1随机接受口服拉米地坦200 mg、100 mg或安慰剂,在偏头痛发作4小时内治疗,共1856例患者治疗了一次发作。
主要发现
- 拉米地坦200 mg组给药后2小时无头痛疼痛比例为32.2%,安慰剂组为15.3%(OR 2.6,95%CI 2.0-3.6,p<0.001)。
- 拉米地坦100 mg组给药后2小时无头痛疼痛比例为28.2%,安慰剂组为15.3%(OR 2.2,95%CI 1.6-3.0,p<0.001)。
- 拉米地坦200 mg组给药后2小时无最困扰症状比例为40.7%,安慰剂组为29.5%(OR 1.6,95%CI 1.3-2.1,p<0.001)。
- 拉米地坦100 mg组给药后2小时无最困扰症状比例为40.9%,安慰剂组为29.5%(OR 1.7,95%CI 1.3-2.2,p<0.001)。
- 不良事件大多为轻度或中度。
关键数值与推荐
- 本研究提供I级证据表明,对于成人偏头痛患者,拉米地坦增加治疗偏头痛发作后2小时无头痛疼痛的受试者比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy and safety of lasmiditan in the acute treatment of migraine. METHODS: Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo and were asked to treat their next migraine attack within 4 hours of onset. Over 48 hours after dosing, patients used an electronic diary to record headache pain and the presence of nausea, phonophobia, and photophobia, one of which was designated their most bothersome symptom (MBS). RESULTS: Of the 1,856 patients who treated an attack, 77.9% had ≥1 cardiovascular risk factors in addition to migraine. Compared with placebo, more patients dosed with lasmiditan 200 mg were free of headache pain at 2 hours after dosing (32.2% vs 15.3%; odds ratio [OR] 2.6, 95% confidence interval [CI] 2.0-3.6, p< 0.001), similar to those dosed with lasmiditan 100 mg (28.2%; OR 2.2, 95% CI 1.6-3.0, p< 0.001). Furthermore, compared with those dosed with placebo, more patients dosed with lasmiditan 200 mg (40.7% vs 29.5%; OR 1.6, 95% CI 1.3-2.1, p< 0.001) and lasmiditan 100 mg (40.9%; OR 1.7, 95% CI, 1.3-2.2, p< 0.001) were free of their MBS at 2 hours after dosing. Adverse events were mostly mild or moderate in intensity. CONCLUSIONS: Lasmiditan dosed at 200 and 100 mg was efficacious and well tolerated in the treatment of acute migraine among patients with a high level of cardiovascular risk factors. CLINICALTRIALSGOV IDENTIFIER: NCT02439320. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.
引用
- Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018. PMID: 30446595. doi:10.1212/WNL.0000000000006641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。